![](https://assets.rebelmouse.io/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy81MTI3NDYwMC9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTc4MDUzMTMwNn0.i8S1-AE20JdGMEv9nJmVhNJrwvxNMRDLkAoLRpPik8w/img.jpg)
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA IN SMALL CELL LUNG CANCER AT WCLC 2024
DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA Amgen (NASDAQ:AMGN) today …